Incomplete immune reconstitution in HIV/AIDS patients on antiretroviral therapy: Challenges of immunological non-responders
X Yang, B Su, X Zhang, Y Liu, H Wu… - Journal of leukocyte …, 2020 - academic.oup.com
The morbidity and mortality of HIV type-1 (HIV-1)-related diseases were dramatically
diminished by the grounds of the introduction of potent antiretroviral therapy, which induces …
diminished by the grounds of the introduction of potent antiretroviral therapy, which induces …
[HTML][HTML] Current status and prospects of HIV treatment
T Cihlar, M Fordyce - Current opinion in virology, 2016 - Elsevier
Highlights•With no available cure, treatment of HIV infection requires life-long therapy.•A
combination of three drugs is the current standard for chronic HIV therapy.•Multiple single …
combination of three drugs is the current standard for chronic HIV therapy.•Multiple single …
Targeting SARS-CoV-2: a systematic drug repurposing approach to identify promising inhibitors against 3C-like proteinase and 2′-O-ribose methyltransferase
The recent pandemic associated with SARS-CoV-2, a virus of the Coronaviridae family, has
resulted in an unprecedented number of infected people. The highly contagious nature of …
resulted in an unprecedented number of infected people. The highly contagious nature of …
Dolutegravir plus two different prodrugs of tenofovir to treat HIV
WDF Venter, M Moorhouse, S Sokhela… - … England Journal of …, 2019 - Mass Medical Soc
Background Two drugs under consideration for inclusion in antiretroviral therapy (ART)
regimens for human immunodeficiency virus (HIV) infection are dolutegravir (DTG) and …
regimens for human immunodeficiency virus (HIV) infection are dolutegravir (DTG) and …
[HTML][HTML] In silico prediction of potential inhibitors for the main protease of SARS-CoV-2 using molecular docking and dynamics simulation based drug-repurposing
Background The rapidly enlarging COVID-19 pandemic caused by the novel SARS-corona
virus-2 is a global public health emergency of an unprecedented level. Unfortunately no …
virus-2 is a global public health emergency of an unprecedented level. Unfortunately no …
Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2016 recommendations of the International Antiviral Society–USA panel
Importance New data and therapeutic options warrant updated recommendations for the use
of antiretroviral drugs (ARVs) to treat or to prevent HIV infection in adults. Objective To …
of antiretroviral drugs (ARVs) to treat or to prevent HIV infection in adults. Objective To …
Efficacy, safety, and tolerability of dolutegravir-rilpivirine for the maintenance of virological suppression in adults with HIV-1: phase 3, randomised, non-inferiority …
Background Lifelong HIV antiretroviral therapy (ART) has prompted an interest in two-drug
regimens to minimise cumulative drug exposure and toxicities. The safety, tolerability, and …
regimens to minimise cumulative drug exposure and toxicities. The safety, tolerability, and …
Efficacy and safety of dolutegravir with emtricitabine and tenofovir alafenamide fumarate or tenofovir disoproxil fumarate, and efavirenz, emtricitabine, and tenofovir …
S Lockman, SS Brummel, L Ziemba… - The Lancet, 2021 - thelancet.com
Background Antiretroviral therapy (ART) during pregnancy is important for both maternal
health and prevention of perinatal HIV-1 transmission; however adequate data on the safety …
health and prevention of perinatal HIV-1 transmission; however adequate data on the safety …
Dolutegravir-based or low-dose efavirenz–based regimen for the treatment of HIV-1
NAMSAL ANRS 12313 Study … - New England Journal of …, 2019 - Mass Medical Soc
Background An efavirenz-based regimen (with a 600-mg dose of efavirenz, known as
EFV600) was the World Health Organization preferred first-line treatment for human …
EFV600) was the World Health Organization preferred first-line treatment for human …
Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 …
PE Sax, A Pozniak, ML Montes, E Koenig, E DeJesus… - The Lancet, 2017 - thelancet.com
Background Integrase strand transfer inhibitors (INSTIs) coadministered with two nucleoside
or nucleotide reverse transcriptase inhibitors (NRTIs) are recommended as first-line …
or nucleotide reverse transcriptase inhibitors (NRTIs) are recommended as first-line …